Tempus AI Q2 Results: Revenue rises 22% YoY, stock slides
Tempus AI (NASDAQ: TEM) reported second-quarter revenue of $382.5 million, rising 22% year-over-year and surpassing Street consensus estimates of $379.7 million. Despite the top-line beat and a narrower-than-expected loss per share of four cents versus an estimated 14 cents loss, shares declined 2.4% in after-hours trading to $43.25.
How this was made
The 30-second read
Why it matters
Near-term valuation pressure appears driven by growth-rate expectations rather than profitability, with the market reacting negatively despite a revenue beat and a small guidance increase. The exclusion of Personalis from guidance keeps the second-half growth narrative dependent on existing operations.
Market read
This is a same-day earnings and guidance update with a clear market reaction, making it actionable for traders managing growth-rate and guidance-execution risk.
What to watch
The article notes $200M of new data and applications licenses and that Personalis is excluded from guidance; traders may be underweighting the near-term cashflow and the optionality from the pending acquisition timeline.
Background
Tempus is positioning growth around AI investments in Oncology Diagnostics and Data Licensing, and it is also pursuing scale via a pending Personalis acquisition.
Ticker impact
Tempus reported Q2 revenue of $382.5M (+22% YoY) and raised FY guidance slightly, yet shares fell 2.4% after hours.
Choppy trading likely persists into the next earnings window as the market tests whether growth re-accelerates or continues to moderate.
The article cites a top-line beat, narrower loss, and a small FY guidance increase, but emphasizes the stock drop and frames it as sensitivity to growth-rate deceleration and the fact that guidance excludes the Personalis acquisition.
Market effects
Signals that investors may be scrutinizing growth rates and AI-driven monetization pace across precision oncology and health-data platforms.
No clear regional spillover beyond US small/mid-cap growth sentiment.
Limited direct global impact; primarily affects US-listed precision oncology and health-data peers via sentiment read-through.
Counterpoint
The modest guidance raise plus EBITDA outlook could be interpreted as conservative underwriting, with upside potential if AI-driven data licensing continues to outgrow diagnostics.
Key entities
- companyTempus AI
Reported Q2 revenue of $382.5M (+22% YoY), narrowed loss, and raised FY revenue guidance slightly; shares fell after hours.
- companyPersonalis
Pending acquisition expected to close late 2026 or early 2027; guidance excludes its impact.
- executiveEric Lefkofsky
CEO attributed growth to AI investments supporting Oncology Diagnostics and Data Licensing.
